M&A trends in Pharma: Takeover activity in the last two and a half years

M&As have been the preferred growth strategy by a majority of Pharma companies. Although mega-mergers certainly create economies of scale and boost pipelines, the long-term effects may not be as favorable as desired. Current trends show the mega-mergers of the past are now a long gone strategy, as now companies are seeking to buy smaller companies for a smaller fee.

The only country which has seen an increase in M&A activity is Japan. Aided by the weak dollar, Japanese firms are keen to enter the lucrative US market. In just over six months there have been four major buy-outs by Japanese companies.

Due to fierce competition and saturation in the US, coupled with a strengthening Indian market, India's generics companies have become more acquirers than targets, either buying directly in the US or indirectly by acquiring a less costly European firm.

Read more...

• Jacobsen Pharma A/S (20/07/2010)
• Pharma Marketing 2010 (20/07/2010)
• Achieving preferential patient-access through innovative agreements with payers (09/07/2010)

• Pharmaceutical Company Outlook (13/03/2009)
• Biosimilars: Strategic issues (06/03/2009)
• Trends in Pharmaceutical Portfolio Management (27/02/2009)
• Licesing to Win (24/02/2009)
• Infectious Diseases Vaccine Market Overview (19/02/2009)
• Croatia - Pharmaceuticals and Biotechnology (18/10/2008)
• Leading Drug Delivery Companies and Technologies (14/10/2008)
• Management of Diabetes (14/10/2008)
• Obesity Drug Markets (14/10/2008)

---